Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Takaku T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T. Iriyama N, et al. Among authors: tabayashi t. Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758-4. Online ahead of print. Int J Hematol. 2024. PMID: 38587692
[De novo blast phase of chronic myeloid leukemia with 3q26 abnormality diagnosed by cytogenetic analysis of extramedullary lesion].
Matsunaga T, Naganuma K, Tabayashi T, Kawada T, Sakata N, Takahashi Y, Kimura Y, Anan T, Mitsuhashi T, Kubota Y, Sawada K, Yamashita T, Momose S, Higashi M, Tamaru JI, Kizaki M. Matsunaga T, et al. Among authors: tabayashi t. Rinsho Ketsueki. 2022;63(12):1643-1647. doi: 10.11406/rinketsu.63.1643. Rinsho Ketsueki. 2022. PMID: 36653137 Japanese.
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.
Tokuhira M, Kimura Y, Tabayashi T, Watanabe N, Tsuchiya S, Takaku T, Iriyama N, Sato E, Nakazato T, Mitsumori T, Ishikawa M, Fujita H, Kizaki M, Ando M, Hatta Y, Iwanaga E, Kawaguchi T. Tokuhira M, et al. Among authors: tabayashi t. Int J Hematol. 2023 Aug;118(2):210-220. doi: 10.1007/s12185-023-03606-x. Epub 2023 May 2. Int J Hematol. 2023. PMID: 37129800
Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601.
Shimada K, Ohmachi K, Machida R, Ota S, Itamura H, Tsujimura H, Takayama N, Shimada T, Kurosawa M, Tabayashi T, Shimoyama T, Ohshima K, Miyazaki K, Maruyama D, Kinoshita T, Ando K, Hotta T, Tsukasaki K, Nagai H. Shimada K, et al. Among authors: tabayashi t. Ann Hematol. 2024 Jun;103(6):2021-2031. doi: 10.1007/s00277-024-05620-3. Epub 2024 Jan 27. Ann Hematol. 2024. PMID: 38280061 Free PMC article. Clinical Trial.
[Acute lymphoblastic leukemia with "masked" Philadelphia chromosome].
Naganuma K, Tabayashi T, Kawada T, Sakata N, Takahashi Y, Kimura Y, Anan T, Mitsuhashi T, Kubota Y, Kizaki M. Naganuma K, et al. Among authors: tabayashi t. Rinsho Ketsueki. 2022;63(11):1525-1529. doi: 10.11406/rinketsu.63.1525. Rinsho Ketsueki. 2022. PMID: 36476792 Japanese.
Prognostic impact of the UK Myeloma Research Alliance Risk Profile in transplant-ineligible patients with multiple myeloma who received a melphalan, prednisolone, and bortezomib regimen: A supplementary analysis of JCOG1105.
Suzuki T, Maruyama D, Machida R, Kataoka T, Fukushima N, Takayama N, Ohba R, Omachi K, Imaizumi Y, Tokunaga M, Katsuya H, Yoshida I, Sunami K, Kurosawa M, Kubota N, Morimoto H, Kobayashi M, Yamamoto K, Kameoka Y, Kagami Y, Tabayashi T, Maruta M, Kobayashi T, Iida S, Nagai H. Suzuki T, et al. Among authors: tabayashi t. Hematol Oncol. 2023 Aug;41(3):590-593. doi: 10.1002/hon.3103. Epub 2022 Nov 30. Hematol Oncol. 2023. PMID: 36416678 No abstract available.
The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders.
Tokuhira M, Tanaka Y, Takahashi Y, Kimura Y, Tomikawa T, Anan T, Watanabe J, Sagawa M, Higashi M, Momose S, Amano K, Tabayashi T, Nakaseko R, Tamaru JI, Kizaki M. Tokuhira M, et al. Among authors: tabayashi t. J Clin Exp Hematop. 2020 Jun 20;60(2):41-50. doi: 10.3960/jslrt.19039. Epub 2020 May 13. J Clin Exp Hematop. 2020. PMID: 32404570 Free PMC article.
40 results